ArticleAngewandte Chemie (International ed. in English)2026
Chemical Synthesis of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii Capsular Polysaccharide Fragments as Leads for Cross-Protection.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Synthesis of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii Capsular Polysaccharide Fragments as Leads for Cross-Protection.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pseudomonas aeruginosa and Staphylococcus aureus are listed by the World Health Organization as high-priority multidrug-resistant (MDR) pathogens, whereas Acinetobacter baumannii is classified as the critical-priority group. These bacteria cause life-threatening infections such as severe bloodstream, nosocomial, urinary tract, and soft-tissue infections. Their cell surfaces display complex and structurally distinct glycans absent in host cells, making them targets for glycoconjugate vaccine and diagnostic research. In this study, we report the chemical synthesis of mono- and oligosaccharide fragments derived from three ESKAPE pathogens, P. aeruginosa O11, S. aureus (CP5, CP8, and strain M), and A. baumannii (S34 and O5), as well as Plesiomonas shigelloides O1. Glycan microarray screening revealed three epitopes exhibiting strong cross-reactive immunogenicity against P. aeruginosa, S. aureus, and A. baumannii, demonstrating that a trisaccharide represents the minimal epitope required to elicit cross-protective immune responses. The key features of P. aeruginosa O11 trisaccharide synthesis involve efficient assembly of a 1,2-cis-linked l-FucNAc-linker motif, followed by regioselective glycosylation at O3 and subsequently at O2 of the d-Glc-l-FucNAc-linker disaccharide. The same strategy was applied for assembling its tetrasaccharide fragment. Additionally, β-mannosylation and 1,2-cis-d-FucNAc linkage formations were optimized for the S. aureus CP8 fragment, establishing a versatile route toward bacterial glycans relevant for vaccine and diagnostic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.